These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 19446911)

  • 1. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up.
    Aw MM; Dhawan A; Samyn M; Bargiota A; Mieli-Vergani G
    J Hepatol; 2009 Jul; 51(1):156-60. PubMed ID: 19446911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis.
    Hlivko JT; Shiffman ML; Stravitz RT; Luketic VA; Sanyal AJ; Fuchs M; Sterling RK
    Clin Gastroenterol Hepatol; 2008 Sep; 6(9):1036-40. PubMed ID: 18586559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy.
    Inductivo-Yu I; Adams A; Gish RG; Wakil A; Bzowej NH; Frederick RT; Bonacini M
    Clin Gastroenterol Hepatol; 2007 Jul; 5(7):799-802. PubMed ID: 17509945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis.
    Efe C; Taii HA; Ytting H; Aehling N; Bhanji RA; Hagström H; Purnak T; Muratori L; Werner M; Muratori P; Klintman D; Schiano TD; Montano-Loza AJ; Berg T; Larsen FS; Alkhouri N; Ozaslan E; Heneghan MA; Yoshida EM; Wahlin S
    Dig Dis Sci; 2018 May; 63(5):1348-1354. PubMed ID: 29569003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients.
    Zachou K; Gatselis N; Papadamou G; Rigopoulou EI; Dalekos GN
    J Hepatol; 2011 Sep; 55(3):636-646. PubMed ID: 21238519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus.
    Chatur N; Ramji A; Bain VG; Ma MM; Marotta PJ; Ghent CN; Lilly LB; Heathcote EJ; Deschenes M; Lee SS; Steinbrecher UP; Yoshida EM
    Liver Int; 2005 Aug; 25(4):723-7. PubMed ID: 15998421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience.
    Wolf DC; Bojito L; Facciuto M; Lebovics E
    Dig Dis Sci; 2009 Nov; 54(11):2519-22. PubMed ID: 19082888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis.
    Efe C; Hagström H; Ytting H; Bhanji RA; Müller NF; Wang Q; Purnak T; Muratori L; Werner M; Marschall HU; Muratori P; Gunşar F; Klintman D; Parés A; Heurgué-Berlot A; Schiano TD; Cengiz M; May-Sien Tana M; Ma X; Montano-Loza AJ; Berg T; Verma S; Larsen FS; Ozaslan E; Heneghan MA; Yoshida EM; Wahlin S
    Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1950-1956.e1. PubMed ID: 28603052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine.
    Richardson PD; James PD; Ryder SD
    J Hepatol; 2000 Sep; 33(3):371-5. PubMed ID: 11019991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of mycophenolate mofetil rescue therapy for resistant acute allograft rejection in pediatric liver transplant recipients.
    Aw MM; Verma A; Rela M; Heaton N; Mieli-Vergani G; Dhawan A
    Liver Transpl; 2008 Sep; 14(9):1303-8. PubMed ID: 18756458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis.
    Snijders RJALM; Stoelinga AEC; Gevers TJG; Pape S; Biewenga M; Tushuizen ME; Verdonk RC; de Jonge HJM; Vrolijk JM; Bakker SF; Vanwolleghem T; de Boer YS; Baven Pronk MAMC; Beuers U; van der Meer AJ; Gerven NMFV; Sijtsma MGM; van Eijck BC; van IJzendoorn MC; van Herwaarden M; van den Brand FF; Korkmaz KS; van den Berg AP; Guichelaar MMJ; Levens AD; van Hoek B; Drenth JPH;
    J Hepatol; 2024 Apr; 80(4):576-585. PubMed ID: 38101756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis.
    Zachou K; Gatselis NK; Arvaniti P; Gabeta S; Rigopoulou EI; Koukoulis GK; Dalekos GN
    Aliment Pharmacol Ther; 2016 May; 43(10):1035-47. PubMed ID: 26991238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil as second line therapy in autoimmune hepatitis?
    Hennes EM; Oo YH; Schramm C; Denzer U; Buggisch P; Wiegard C; Kanzler S; Schuchmann M; Boecher W; Galle PR; Adams DH; Lohse AW
    Am J Gastroenterol; 2008 Dec; 103(12):3063-70. PubMed ID: 18853972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy.
    Roberts SK; Lim R; Strasser S; Nicoll A; Gazzola A; Mitchell J; Siow W; Khoo T; Hamarneh Z; Weltman M; Gow P; Janko N; Tse E; Mishra G; Cheng EH; Levy M; Cheng W; Sood S; Skoien R; Mitchell J; Zekry A; George J; MacQuillan G; Wigg A; Stuart K; Sievert W; McCaughan G;
    Clin Gastroenterol Hepatol; 2018 Feb; 16(2):268-277. PubMed ID: 29050991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil as a rescue therapy for autoimmune hepatitis patients who are not responsive to standard therapy.
    Fallatah HI; Akbar HO
    Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):517-22. PubMed ID: 21780898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of mycophenolate mofetil with standard treatment for autoimmune hepatitis: a meta-analysis.
    Yu ZJ; Zhang LL; Huang TT; Zhu JS; He ZB
    Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):873-877. PubMed ID: 31150366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of children and young adults with autoimmune hepatitis treated with cyclosporine.
    Nastasio S; Sciveres M; Matarazzo L; Malaventura C; Cirillo F; Riva S; Maggiore G
    Dig Liver Dis; 2019 May; 51(5):712-718. PubMed ID: 30502231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis.
    Santiago P; Schwartz I; Tamariz L; Levy C
    Aliment Pharmacol Ther; 2019 Apr; 49(7):830-839. PubMed ID: 30761563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes.
    Baven-Pronk AM; Coenraad MJ; van Buuren HR; de Man RA; van Erpecum KJ; Lamers MM; Drenth JP; van den Berg AP; Beuers UH; den Ouden J; Koek GH; van Nieuwkerk CM; Bouma G; Brouwer JT; van Hoek B
    Aliment Pharmacol Ther; 2011 Aug; 34(3):335-43. PubMed ID: 21668459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis.
    Park SW; Um SH; Lee HA; Kim SH; Sim Y; Yim SY; Seo YS; Ryu HS
    Clin Mol Hepatol; 2016 Jun; 22(2):281-5. PubMed ID: 27246353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.